In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Hospital Antibiotic's Closely Watched Launch

Executive Summary

Cubist ultimately wants its new hospital antibiotic Cubicin to replace the widely used vancomycin. To do that, it's got to demonstrate that Cubicin, recently approved for a single indication, is safe and effective for a broad spectrum of hard-to-treat infections. As the first company in four years to launch a new hospital antibiotic, Cubist may be a model for the handful of other small companies seeking to capitalize on the opportunity. These start-ups may be better suited than Big Pharma to address what experts see as an important but limited unmet medical need.
Advertisement
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002312

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel